Zhou M X, Chang T M
Artificial Cells and Organs Research Centre, McGill University, Montreal, Quebec, Canada.
J Microencapsul. 1988 Jan-Mar;5(1):27-36. doi: 10.3109/02652048809036720.
Low molecular weight polylactic acid (PLA) microparticles containing prostaglandin E2 were prepared. An average particle size of 30 micron was obtained by grinding at low temperature. These particles were further treated by heating to modify the shape and the release pattern. Microscopic studies showed that the modified particles had a smoother surface than the non-modified particles. The drug was also incorporated into PLA microcapsules using the solvent evaporation process, but the incorporation efficiency was lower. We studied the release profiles of modified particles prepared using different molecular weight PLA. The release rate depended on the molecular weight with lower molecular weights having a greater release rate. In addition, the release studies showed different matrix forms made from the same molecular weight PLA had different release patterns. For example, the microcapsules released the drug very slowly whereas the modified particles exhibited a moderate release rate. It was also noted that the matrix release model could describe the release patterns of microcapsules and modified particles very well. However, the release patterns of non-modified microparticles did not follow this model.
制备了含有前列腺素E2的低分子量聚乳酸(PLA)微粒。通过低温研磨获得了平均粒径为30微米的微粒。这些微粒通过加热进一步处理以改变其形状和释放模式。显微镜研究表明,改性微粒的表面比未改性微粒更光滑。药物也通过溶剂蒸发法被包封到PLA微囊中,但其包封效率较低。我们研究了使用不同分子量PLA制备的改性微粒的释放曲线。释放速率取决于分子量,分子量较低时释放速率较高。此外,释放研究表明,由相同分子量PLA制成的不同基质形式具有不同的释放模式。例如,微囊释放药物非常缓慢,而改性微粒表现出适度的释放速率。还注意到,基质释放模型可以很好地描述微囊和改性微粒的释放模式。然而,未改性微粒的释放模式并不符合该模型。